ArticleScientific reports2026
Biogenic selenium extract-mediated and total Convolvulus oxyphyllus extracts suppress IL6 and COX2 expression: insights from LC-MS metabolite profiling and molecular docking.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation plays a crucial role in many chronic diseases with IL-6 and COX-2 being key mediators. The current article explored the anti-inflammatory potential of Convolvulus oxyphyllus extracts, combining phytochemical profiling, molecular docking, and gene expression analysis to elucidate their mechanisms of action. Total alcohol extract and extract-mediated Se-NPs of C. oxyphyllus were evaluated for their ability to modulate IL6 and COX2 expression using quantitative real-time PCR (qRT-PCR). LC-MS investigation was implemented to identify major phytoconstituents, followed by molecular docking to assess the binding interactions of selected most abundant flavonoid compounds (quercetin, daidzein-8-C-glucoside, kaempferol-7-neohesperidoside, and eriodictyol-7-O-neohesperidoside) with COX-2 (PDB ID: 8ET0) and IL-6 (PDB ID: 4N19). Both extract-mediated Se-NPs and total alcohol extract significantly down-regulated IL6 and COX2 expression (69% and 73%, respectively), comparable to Celecoxib. LC-MS profiling revealed the presence of flavonoids as dominant metabolites, alkaloids, coumarins and other constituents. Molecular docking demonstrated strong ligand-target interactions, with eriodictyol-7-O-neohesperidoside showing the highest binding affinity for COX-2 (- 10.2 kcal/mol) and kaempferol-7-neohesperidoside for IL-6 (- 7.4 kcal/mol), surpassing or matching the standard drug Celecoxib. These outcomes emphasize the therapeutic potential of C. oxyphyllus and its constituent phytochemicals as natural anti-inflammatory agents warranting further in vivo validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.